Chairman_NNP &_CC Chief_NNP Executive_NNP Officers_NNPS statement_NN GSK_NNP demonstrates_VBZ continued_JJ strength_NN Building_NN a_DT strong_JJ and_CC diverse_JJ R&D_NNP pipeline_NN people_NNS ._.
The_DT World_NNP Health_NNP Organization_NNP target_NN Acknowledgements_NNP licences_NNS ,_, but_CC gives_VBZ assurances_NNS that_IN this_DT will_MD not_RB of_IN generic_JJ competition_NN ,_, have_VBP seen_VBN their_PRP$ earnings_NNS Key_NNP features_NNS of_IN 2003_CD 2003_CD provided_VBD the_DT clearest_JJS evidence_NN yet_RB of_IN our_PRP$ is_VBZ to_TO eliminate_VB LF_NNP by_IN 2020_CD ,_, by_IN which_WDT time_NN we_PRP During_IN the_DT year_NN there_EX were_VBD a_DT number_NN of_IN changes_NNS be_VB abused_VBN ._.
Nevertheless_RB ,_, the_DT external_JJ pressure_NN fall_NN significantly_RB ._.
success_NN in_IN creating_VBG the_DT most_JJS productive_JJ R&D_NNP expect_VBP to_TO have_VB donated_VBN six_CD billion_CD treatments_NNS of_IN to_TO the_DT Board_NNP ._.
The_DT Board_NNP now_RB benefits_VBZ from_IN the_DT to_TO amend_VB the_DT TRIPS_NNS agreement_NN ,_, which_WDT protects_VBZ organization_NN in_IN the_DT industry_NN ._.
At_IN our_PRP$ R&D_NNP our_PRP$ medicine_NN albendazole_NN ,_, worth_JJ around_IN direct_JJ presence_NN of_IN Dr_NNP Tachi_NNP Yamada_NNP ,_, who_WP has_VBZ intellectual_JJ property_NN ,_, remains_VBZ strong_JJ ._.
2004_CD will_MD be_VB a_DT year_NN of_IN transition_NN for_IN GSK_NNP ._.
By_IN Day_NNP in_IN December_NNP we_PRP demonstrated_VBD how_WRB our_PRP$ $_$ 1_CD billion_CD ._.
This_DT is_VBZ one_CD of_IN the_DT pharmaceutical_JJ great_JJ knowledge_NN and_CC experience_NN in_IN medical_JJ the_DT end_NN of_IN 2004_CD the_DT companys_NNS profile_VBP will_MD be_VB 1_CD New_JJ products_NNS accounted_VBD for_IN 25_CD %_NN re-designed_JJ R&D_NNP operation_NN is_VBZ delivering_VBG a_DT industrys_RB largest_JJS ever_RB donation_NN programs_NNS ._.
practice_NN as_RB well_RB as_IN the_DT pharmaceutical_JJ industry_NN ._.
This_DT is_VBZ not_RB the_DT place_NN to_TO debate_VB the_DT rights_NNS transformed_VBN ._.
As_RB well_RB as_IN having_VBG one_CD of_IN the_DT most_JJS of_IN total_JJ pharmaceutical_JJ turnover_NN ._.
product_NN pipeline_NN of_IN exceptional_JJ diversity_NN ,_, quality_NN We_PRP reduced_VBD the_DT not-for-profit_JJ prices_NNS of_IN our_PRP$ HIV_NNP Three_CD new_JJ Non-Executive_JJ Directors_NNS joined_VBD the_DT and_CC wrongs_NNS of_IN these_DT challenges_NNS to_TO the_DT broadly-based_JJ product_NN portfolios_NNS in_IN the_DT industry_NN ,_, and_CC quantity_NN that_WDT will_MD drive_VB the_DT future_JJ growth_NN treatments_NNS twice_RB in_IN 2003_CD ,_, taking_VBG the_DT price_NN of_IN Board_NNP during_IN the_DT year_NN :_: Larry_NNP Culp_NNP ,_, President_NNP pharmaceutical_JJ industrys_NNS traditional_JJ business_NN from_IN 2005_CD onwards_NNS we_PRP will_MD also_RB have_VB one_CD of_IN the_DT 2_CD Trading_NN profit_NN of_IN 6.9_CD billion_CD on_IN of_IN the_DT company_NN ._.
Combivir_NNP down_RB from_IN $_$ 1.70_CD to_TO just_RB 65_CD cents_NNS a_DT of_IN Danaher_NNP Corporation_NNP :_: Crispin_NNP Davis_NNP ,_, Chief_NNP model_NN ._.
It_PRP is_VBZ the_DT place_NN for_IN us_PRP to_TO reassure_VB lowest_JJS exposures_NNS to_TO patent_NN expiries_NNS measured_VBN as_IN turnover_NN of_IN 21.4_CD billion_CD ._.
However_RB ,_, much_RB more_RBR needs_VBZ to_TO be_VB done_VBN Executive_NNP of_IN Reed_NNP Elsevier_NNP PLC_NNP :_: and_CC Sir_NNP Robert_NNP shareholders_NNS that_IN we_PRP have_VBP every_DT aspect_NN of_IN a_DT percentage_NN of_IN turnover_NN ._.
At_IN the_DT same_JJ time_NN ,_, we_PRP We_PRP now_RB have_VBP 148_CD projects_NNS in_IN clinical_JJ to_TO tackle_VB the_DT enormous_JJ HIV_NNP AIDS_NNP crisis_NN ._.
Real_JJ Wilson_NNP ,_, Chairman_NNP of_IN BG_NNP Group_NNP plc._NN ._.
They_PRP each_DT that_IN model_NN under_IN review_NN in_IN order_NN to_TO continue_VB expect_VB to_TO see_VB a_DT big_JJ increase_NN in_IN the_DT number_NN of_IN 3_CD Ten_CD major_JJ products_NNS recorded_VBN development_NN ._.
These_DT span_VBP a_DT variety_NN of_IN therapeutic_JJ progress_NN will_MD only_RB be_VB made_VBN if_IN responsibility_NN is_VBZ bring_VB many_JJ years_NNS of_IN experience_NN and_CC successful_JJ the_DT development_NN of_IN medicines_NNS on_IN a_DT basis_NN which_WDT major_JJ new_JJ compounds_NNS entering_VBG Phase_NN III_NNP trials_NNS double-digit_JJ growth_NN ._.
areas_NNS and_CC encompass_VB a_DT number_NN of_IN pioneering_JJ shared_VBN by_IN all_DT sectors_NNS of_IN global_JJ society_NN track_NN records_NNS in_IN different_JJ industries_NNS ._.
Their_PRP$ reconciles_NNS our_PRP$ responsibility_NN to_TO society_NN with_IN a_DT fair_JJ from_IN our_PRP$ promising_JJ pipeline_NN ._.
approaches_NNS to_TO treating_VBG patients_NNS ,_, including_VBG governments_NNS ,_, international_JJ agencies_NNS and_CC undoubted_JJ skills_NNS further_RBR strengthen_VB the_DT Board_NNP ._.
We_PRP are_VBP determined_VBN to_TO 4_CD Regulatory_NNP approval_NN for_IN ten_NN exciting_JJ new_JJ compounds_NNS in_IN the_DT areas_NNS of_IN companies_NNS such_JJ as_IN GSK_NNP ._.
change_NN with_IN the_DT times_NNS imaginatively_RB ,_, flexibly_RB and_CC Broad_NNP product_NN portfolio_NN drives_VBZ growth_NN important_JJ new_JJ products_NNS and_CC new_JJ indications_NNS ._.
The_DT Sir_NNP Roger_NNP Hurn_NNP and_CC Paul_NNP Allaire_NNP left_VBD the_DT Board_NNP effectively_RB ,_, and_CC to_TO fight_VB for_IN what_WP we_PRP believe_VBP will_MD GSKs_NNS ability_NN to_TO continue_VB delivering_VBG robust_JJ 148_CD projects_NNS include_VBP 83_CD new_JJ chemical_NN entities_NNS We_PRP are_VBP very_RB proud_JJ of_IN our_PRP$ global_JJ community_NN in_IN June_NNP ._.
Dr_NNP Michle_NNP Barzach_NNP ,_, John_NNP McArthur_NNP best_JJS serve_VBP the_DT long_JJ term_NN interests_NNS of_IN GSK_NNP as_IN one_CD pharmaceuticals_NNS sales_NNS growth_NN ,_, despite_IN these_DT NCEs_NNS ,_, 45_CD product_NN line_NN extensions_NNS PLEs_NNS and_CC 20_CD investment_NN of_IN 338_CD million_CD ,_, 5.3_CD per_IN cent_NN of_IN the_DT and_CC Donald_NNP McHenry_NNP will_MD step_VB down_RB from_IN the_DT of_IN the_DT worlds_NNS leading_VBG producers_NNS of_IN medicines_NNS ._.
generic_JJ challenges_NNS ,_, is_VBZ primarily_RB due_JJ to_TO its_PRP$ vaccines_NNS ._.
Forty_CD six_CD of_IN the_DT NCEs_NNS are_VBP now_RB in_IN clinical_JJ Groups_NNS pre-tax_JJ profit_NN ._.
This_DT included_VBD 125_CD million_CD Board_NNP after_IN the_DT AGM_NNP in_IN May_NNP ._.
We_PRP express_VBP our_PRP$ exceptionally_RB broad_JJ product_NN portfolio_NN of_IN fastphases_NNS II_NNP and_CC III_NNP registration_NN and_CC we_PRP expect_VBP to_TO for_IN the_DT Group_NNP 's_POS Patient_NNP Assistance_NNP Programs_NNP and_CC appreciation_NN to_TO each_DT of_IN them_PRP for_IN their_PRP$ Robust_JJ financial_JJ performance_NN in_IN 2003_CD growing_VBG ,_, high-value_JJ products_NNS ._.
GSK_NNP is_VBZ a_DT global_JJ make_VBP a_DT record_NN number_NN of_IN filings_NNS over_IN the_DT next_JJ other_JJ initiatives_NNS for_IN low-income_JJ groups_NNS in_IN the_DT contribution_NN to_TO the_DT company_NN and_CC for_IN their_PRP$ During_IN 2003_CD ,_, our_PRP$ business_NN performance_NN earnings_NNS leader_NN in_IN several_JJ therapeutic_JJ areas_NNS including_VBG five_CD years_NNS ._.
As_IN many_JJ as_IN 20_CD of_IN these_DT compounds_NNS USA_NNP and_CC 105_CD million_CD of_IN humanitarian_JJ product_NN dedicated_VBN and_CC effective_JJ service_NN to_TO the_DT Board_NNP ._.
per_IN share_NN grew_VBD ten_CD per_IN cent_NN ,_, which_WDT was_VBD in_IN line_NN respiratory_JJ ,_, anti-viral_JJ ,_, central_JJ nervous_JJ system_NN ,_, have_VBP the_DT potential_NN to_TO reach_VB blockbuster_NN status_NN ._.
with_IN the_DT guidance_NN we_PRP had_VBD issued_VBN ._.
Trading_NN profit_NN diabetes_NN and_CC vaccines_NNS ._.
In_IN conclusion_NN ,_, on_IN behalf_NN of_IN the_DT Board_NNP and_CC the_DT rose_VBD nine_CD per_IN cent_NN to_TO 6.9_CD billion_CD and_CC we_PRP had_VBD an_DT Included_VBN in_IN the_DT many_JJ promising_JJ compounds_NNS Governance_NNP Corporate_NNP Executive_NNP Team_NNP ,_, we_PRP thank_VBP you_PRP ,_, our_PRP$ operating_NN cash_NN flow_NN of_IN 7.0_CD billion_CD ._.
We_PRP also_RB The_DT company_NN now_RB has_VBZ ten_VBN major_JJ products_NNS highlighted_VBN in_IN December_NNP were_VBD :_: 016_CD ,_, a_DT first_JJ of_IN its_PRP$ The_DT Financial_NNP Reporting_NNP Council_NNP 's_POS new_JJ Combined_VBN shareholders_NNS ,_, for_IN your_PRP$ continued_JJ support_NN raised_VBD the_DT dividend_NN to_TO 41_CD pence_NN ._.
accounting_NN for_IN 7.6_CD billion_CD of_IN sales_NNS growing_VBG kind_NN dual_JJ kinase_NN inhibitor_NN for_IN the_DT treatment_NN of_IN Code_NNP on_IN Corporate_NNP Governance_NNP was_VBD published_VBN through_IN this_DT challenging_JJ time_NN ._.
These_DT include_VBP breast_NN and_CC lung_NN cancer_NN :_: Cervarix_NNP ,_, a_DT vaccine_NN with_IN in_IN 2003_CD ._.
The_DT Board_NNP supports_VBZ the_DT New_NNP Code_NNP and_CC Total_NNP pharmaceutical_JJ turnover_NN grew_VBD five_CD per_IN cent_NN Seretide_NNP Advair_NNP for_IN asthma_NN and_CC chronic_JJ Trading_NN Profit_NN growth_NN the_DT potential_NN to_TO prevent_VB more_JJR than_IN 70_CD per_IN cent_NN has_VBZ moved_VBN quickly_RB to_TO bring_VB GSK_NNP 's_POS governance_NN to_TO just_RB over_IN 18_CD billion_CD ,_, with_IN US_NNP sales_NNS also_RB up_IN obstructive_JJ pulmonary_JJ disease_NN COPD_NNP which_WDT of_IN cervical_JJ cancers_NNS :_: 162_CD ,_, a_DT next-generation_JJ procedures_NNS substantially_RB in_IN line_NN with_IN the_DT best_JJS five_CD per_IN cent_NN to_TO 9.4_CD billion_CD ._.
This_DT achievement_NN grew_VBD 39_CD per_IN cent_NN during_IN the_DT year_NN to_TO 2.2_CD billion_CD ,_, anti-depressant_JJ :_: Lp-PLA2_NN inhibitors_NNS which_WDT target_VBP practices_NNS that_WDT flow_VBP from_IN the_DT Code_NNP ._.
confirms_VBZ the_DT underlying_JJ strength_NN and_CC resilience_NN of_IN and_CC is_VBZ now_RB one_CD of_IN the_DT top_JJ ten_NN pharmaceutical_JJ Trading_NN Profit_NN a_DT newly_RB identified_VBN risk_NN factor_NN for_IN heart_NN disease_NN :_: our_PRP$ business_NN ,_, particularly_RB given_VBN continued_VBN generic_JJ brands_NNS in_IN the_DT world_NN ._.
Our_PRP$ diabetes_NN treatments_NNS odiparcil_NN ,_, a_DT novel_NN anti-blood_JJ clotting_NN treatment_NN ,_, up_IN 9_CD %_NN to_TO erosion_NN during_IN the_DT year_NN to_TO sales_NNS of_IN Augmentin_NNP Avandia_NNP Avandamet_NNP also_RB continue_VBP to_TO perform_VB Sir_NNP Christopher_NNP Hogg_NNP JP_NNP Garnier_NNP and_CC 381_CD ,_, the_DT first_JJ dual_JJ action_NN COX-2_NN inhibitor_NN and_CC the_DT introduction_NN of_IN generic_JJ competition_NN to_TO well_RB ,_, with_IN sales_NNS of_IN 0.9_CD billion_CD ,_, up_RB 24_CD per_IN cent_NN ._.
Chairman_NNP Chief_NNP Executive_NNP Officer_NNP 6.9_CD billion_CD targeting_VBG both_DT inflammatory_JJ and_CC neuropathic_JJ Paxil_NNP in_IN September_NNP ._.
Products_NNPS such_JJ as_IN Valtrex_NNP for_IN herpes_NNS and_CC Lamictal_JJ pain_NN ._.
Building_NN on_IN our_PRP$ strong_JJ heritage_NN in_IN for_IN epilepsy_NN are_VBP growing_VBG very_RB strongly_RB and_CC are_VBP respiratory_JJ medicine_NN ,_, we_PRP are_VBP also_RB developing_VBG a_DT The_DT Consumer_NNP Healthcare_NNP business_NN also_RB did_VBD well_RB ,_, now_RB approaching_VBG blockbuster_NN status_NN ._.
Also_RB ,_, both_DT next-generation_JJ Seretide_NNP Advair_NNP a_DT once-daily_JJ making_VBG a_DT trading_NN profit_NN of_IN 603_CD million_CD for_IN the_DT year_NN ,_, our_PRP$ vaccines_NNS and_CC HIV_NNP AIDS_NNP businesses_NNS have_VBP sales_NNS combination_NN of_IN a_DT new_JJ long-acting_JJ corticosteroid_NN ,_, up_RB 16_CD per_IN cent_NN ._.
698_CD ,_, and_CC a_DT long-acting_JJ selective_JJ beta2_JJ agonist_NN ,_, 797_CD ,_, developed_VBN with_IN Theravance_NNP Inc._NNP 2004_CD a_DT year_NN of_IN transition_NN before_IN returning_VBG New_NNP product_NN launches_NNS in_IN 2003_CD and_CC 2004_CD to_TO growth_NN in_IN 2005_CD Several_JJ new_JJ and_CC important_JJ products_NNS were_VBD Corporate_JJ responsibility_NN 2004_CD will_MD be_VB a_DT particularly_RB challenging_JJ year_NN as_IN introduced_VBN in_IN 2003_CD ._.
Highlights_NNS included_VBD US_NNP Corporate_NNP responsibility_NN has_VBZ particular_JJ resonance_NN we_PRP see_VBP the_DT full_JJ impact_NN of_IN generic_JJ competition_NN launches_NNS of_IN Wellbutrin_NNP XL_NNP ,_, a_DT new_JJ and_CC improved_VBN for_IN the_DT pharmaceutical_JJ sector_NN ._.
Our_PRP$ business_NN is_VBZ to_TO Paxil_NNP and_CC the_DT introduction_NN of_IN generic_JJ version_NN of_IN the_DT anti-depressant_JJ ,_, and_CC Levitra_NNP for_IN 01_CD 02_CD 03_CD creating_VBG medicines_NNS to_TO treat_VB and_CC prevent_VB disease_NN Wellbutrin_NNP ._.
Together_RB ,_, these_DT products_NNS had_VBD erectile_JJ dysfunction_NN ._.
Approval_NN was_VBD received_VBN These_DT are_VBP based_VBN on_IN business_NN performance_NN results_NNS ._.
something_NN that_WDT society_NN needs_NNS and_CC values_NNS ._.
At_IN the_DT US_NNP sales_NNS of_IN 2.1_CD billion_CD last_JJ year_NN ._.
For_IN most_JJS for_IN Lexiva_NNP for_IN HIV_NNP AIDS_NNP ,_, Advair_NNP for_IN COPD_NNP and_CC All_DT percentage_NN growth_NN rates_NNS are_VBP at_IN constant_JJ same_JJ time_NN ,_, healthcare_NN and_CC the_DT way_NN it_PRP is_VBZ delivered_VBN companies_NNS ,_, a_DT threat_NN to_TO sales_NNS on_IN this_DT scale_NN would_MD Lamictal_VB for_IN bi-polar_JJ disorder_NN in_IN the_DT USA_NNP ,_, and_CC exchange_NN rates_NNS ,_, unless_IN otherwise_RB stated_VBN ._.
and_CC funded_JJ provoke_VBP much_JJ debate_NN ._.
But_CC we_PRP expect_VBP to_TO be_VB able_JJ to_TO Avandamet_NNP for_IN diabetes_NN in_IN Europe_NNP ._.
See_NNP Business_NNP Operating_NNP Review_NNP page_NN 22_CD ._.
Corporate_JJ Responsibility_NN Report_NNP sets_VBZ out_RP the_DT weather_NN the_DT impact_NN well_RB partly_RB because_IN of_IN our_PRP$ issues_NNS that_IN we_PRP face_VBP in_IN this_DT area_NN and_CC explains_VBZ size_NN ,_, partly_RB through_IN the_DT introduction_NN of_IN improved_VBN We_PRP plan_VBP to_TO make_VB several_JJ significant_JJ product_NN how_WRB we_PRP are_VBP addressing_VBG them_PRP ._.
Where_WRB possible_JJ ,_, versions_NNS of_IN these_DT medicines_NNS and_CC partly_RB by_IN driving_VBG launches_NNS and_CC filings_NNS during_IN 2004_CD ._.
These_DT include_VBP :_: performance_NN measures_NNS are_VBP included_VBN to_TO show_VB growth_NN of_IN the_DT other_JJ key_JJ products_NNS in_IN our_PRP$ broad_JJ solifenacin_NN for_IN over-active_JJ bladder_NN developed_VBD our_PRP$ progress_NN ._.
In_IN fact_NN ,_, we_PRP expect_VBP to_TO be_VB able_JJ to_TO deliver_VB with_IN our_PRP$ partner_NN Yamanouchi_NNP Pharmaceuticals_NNP 2004_CD earnings_NNS per_IN share_NN EPS_NNP at_IN least_JJS in_IN line_NN with_IN Ltd_NNP of_IN Japan_NNP :_: Avandaryl_NNP ,_, a_DT fixed-dose_JJ Significant_JJ achievements_NNS this_DT year_NN include_VBP the_DT business_NN performance_NN EPS_NNP in_IN 2003_CD at_IN constant_JJ combination_NN treatment_NN which_WDT will_MD further_RBR extend_VB progress_NN we_PRP are_VBP making_VBG in_IN our_PRP$ programs_NNS for_IN exchange_NN rates_NNS ,_, before_IN returning_VBG to_TO growth_NN in_IN the_DT Avandia_NNP family_NN of_IN treatments_NNS for_IN type_NN 2_CD the_DT developing_VBG world_NN ,_, such_JJ as_IN our_PRP$ efforts_NNS to_TO 2005_CD ._.
This_DT will_MD represent_VB a_DT solid_JJ achievement_NN for_IN diabetes_NN :_: and_CC Epivir_NNP plus_CC Ziagen_NNP ,_, the_DT first_JJ onceeliminate_JJ lymphatic_JJ filariasis_NN LF_NNP or_CC elephantiasis_NN ,_, GSK_NNP ._.
Many_JJ other_JJ pharmaceutical_JJ companies_NNS ,_, daily_JJ combination_NN HIV_NNP AIDS_NNP treatment_NN to_TO be_VB a_DT debilitating_VBG disease_NN affecting_VBG 120_CD million_CD which_WDT have_VBP faced_VBN a_DT similar_JJ loss_NN of_IN sales_NNS as_IN a_DT result_NN available_JJ in_IN a_DT single_JJ tablet_NN ._.
02_CD Annual_JJ Review_NNP 2003_CD million_CD 6,053_CD 6,694_CD 6,920_CD A_DT day_NN to_TO deliver_VB Our_PRP$ unique_JJ R&D_NNP structure_NN starts_VBZ to_TO deliver_VB ._.
GSKs_NNS radical_JJ redesign_NN of_IN its_PRP$ R&D_NNP organization_NN is_VBZ a_DT bold_JJ move_NN to_TO tackle_VB the_DT problem_NN of_IN R&D_NNP productivity_NN ,_, a_DT real_JJ challenge_NN to_TO the_DT global_JJ pharmaceutical_JJ industry_NN ._.
The_DT impact_NN of_IN the_DT reorganisation_NN can_MD now_RB be_VB seen_VBN in_IN GSKs_NNS broad_JJ and_CC deep_JJ pipeline_NN of_IN medicines_NNS across_IN a_DT spectrum_NN of_IN key_JJ therapeutic_JJ areas_NNS ._.
The_DT projects_NNS that_WDT GSK_NNP now_RB has_VBZ in_IN clinical_JJ development_NN comprise_VBP a_DT number_NN of_IN pioneering_JJ approaches_NNS Asthma_NNP affects_VBZ 100-150_CD million_CD people_NNS worldwide_JJ ,_, killing_VBG 180,000_CD each_DT We_PRP have_VBP vaccines_NNS in_IN clinical_JJ development_NN against_IN numerous_JJ to_TO treating_VBG patients_NNS in_IN need_NN ._.
Our_PRP$ new_JJ structure_NN is_VBZ working_VBG well_RB ,_, said_VBD Tachi_NNP Yamada_NNP ,_, Chairman_NNP of_IN R&D_NNP ._.
Seretide_NNP Advair_NNP has_VBZ revolutionised_VBN the_DT treatment_NN of_IN asthma_NN and_CC chronic_JJ diseases_NNS affecting_VBG all_DT age_NN brackets_NNS ,_, from_IN children_NNS to_TO the_DT developing_VBG more_JJR quality_NN compounds_NNS than_IN ever_RB before_RB ._.
This_DT is_VBZ enabling_VBG us_PRP to_TO renew_VB our_PRP$ pipeline_NN in_IN disease_NN areas_NNS obstructive_JJ pulmonary_JJ disease_NN COPD_NNP ._.
One_CD of_IN our_PRP$ development_NN compounds_NNS ,_, elderly_JJ ,_, and_CC in_IN all_DT regions_NNS ,_, from_IN the_DT developed_VBN to_TO the_DT 685698_CD ,_, is_VBZ a_DT third_JJ generation_NN inhaled_VBD corticosteroid_JJ ._.
It_PRP promises_VBZ to_TO be_VB a_DT oncedeveloping_JJ world_NN ._.
In_IN 2004_CD ,_, we_PRP plan_VBP to_TO file_VB our_PRP$ Rotarix_NNP vaccine_NN where_WRB we_PRP are_VBP leaders_NNS such_JJ as_IN respiratory_JJ and_CC psychiatry_JJ and_CC to_TO build_VB strong_JJ portfolios_NNS in_IN areas_NNS such_JJ as_IN oncology_JJ a-day_JJ treatment_NN and_CC to_TO offer_VB greater_JJR potency_NN ._.
to_TO help_VB stem_VB rotavirus_NNS gastroenteritis_NNS ,_, a_DT disease_NN that_WDT is_VBZ and_CC cardiovascular_JJ disease_NN ._.
estimated_VBN to_TO lead_VB to_TO the_DT death_NN of_IN one_CD child_NN every_DT minute_NN ._.
Two_CD thirds_NNS of_IN Americans_NNPS are_VBP obese_JJ or_CC overweight_NN :_: one_CD in_IN three_CD Americans_NNPS born_VBN in_IN 2000_CD will_MD become_VB diabetic_JJ ._.
Forty_CD two_CD million_CD people_NNS worldwide_JJ live_VBP with_IN HIV_NNP ._.
Our_PRP$ 181771_CD compound_NN is_VBZ an_DT appetite_NN suppressant_NN that_WDT creates_VBZ a_DT natural_JJ feeling_NN of_IN fullness_NN while_IN our_PRP$ SGLT2_CD inhibitor_NN is_VBZ a_DT new_JJ approach_NN to_TO diabetes_NN treatment_NN ._.
GSK_NNP also_RB has_VBZ development_NN compounds_NNS against_IN HIV_NNP in_IN all_DT phases_NNS of_IN its_PRP$ replication_NN cycle_NN ._.
Our_PRP$ CEDD_NNP structure_NN Vaccines_NNP Metabolic_NNP &_CC Viral_NNP diseases_NNS Respiratory_NNP &_CC Inflammatory_NNP diseases_NNS Microbial_NNP ,_, Musculoskeletal_NNP &_CC Cardiovascular_NNP &_CC Urogenital_NNP diseases_NNS Neurological_NNP &_CC Gastrointestinal_NNP diseases_NNS Psychiatry_NNP Biopharmaceuticals_NNP Proliferative_NNP diseases_NNS Cancer_NNP affects_VBZ one_CD in_IN three_CD people_NNS ._.
Our_PRP$ 572016_CD compound_NN ,_, Our_PRP$ new_JJ CEDD_NNP was_VBD launched_VBN in_IN January_NNP 2004_CD with_IN the_DT aim_NN of_IN extending_VBG a_DT dual_JJ kinase_NN inhibitor_NN being_VBG investigated_VBN for_IN the_DT treatment_NN GSKs_NNP R&D_NNP model_NN through_IN monoclonal_JJ antibodies_NNS ,_, therapeutic_JJ vaccines_NNS and_CC of_IN solid_JJ tumors_NNS ,_, is_VBZ a_DT first_JJ of_IN its_PRP$ kind_NN ._.
It_PRP may_MD help_VB convert_VB the_DT recombinant_JJ therapeutic_JJ proteins_NNS ._.
Biopharmaceuticals_NNS is_VBZ a_DT field_NN where_WRB we_PRP are_VBP Cardiovascular_NNP disease_NN is_VBZ the_DT number_NN one_CD killer_NN in_IN the_DT western_JJ management_NN of_IN some_DT cancers_NNS to_TO chronic_JJ stable_JJ disease_NN states_NNS ._.
progressing_VBG a_DT growing_VBG number_NN of_IN assets_NNS in_IN our_PRP$ early_JJ stage_NN pipeline_NN ._.
world_NN and_CC a_DT growing_VBG problem_NN in_IN developing_VBG countries_NNS as_RB well_RB ._.
We_PRP are_VBP pioneering_JJ a_DT novel_JJ class_NN of_IN compounds_NNS that_WDT sharply_RB lower_JJR the_DT activity_NN of_IN an_DT enzyme_NN associated_VBN with_IN cardiovascular_JJ Diseases_NNS in_IN our_PRP$ CEDD_NNP portfolio_NN encompass_VB some_DT of_IN the_DT worlds_NNS Psychiatric_JJ illnesses_NNS include_VBP schizophrenia_NN ,_, anxiety_NN and_CC addiction_NN ._.
This_DT new_JJ approach_NN could_MD lead_VB to_TO the_DT next_JJ generation_NN highest_JJS un-met_JJ medical_JJ needs_NNS multiple_JJ sclerosis_NN ,_, Alzheimers_NNP The_NNP mission_NN of_IN our_PRP$ CEDD_NNP is_VBZ to_TO provide_VB direction_NN and_CC light_NN to_TO the_DT minds_NNS of_IN drugs_NNS to_TO reduce_VB cardiovascular_JJ events_NNS and_CC deaths_NNS ._.
disease_NN ,_, irritable_JJ bowel_NN syndrome_NN and_CC migraine_NN ._.
Our_PRP$ compound_NN of_IN patients_NNS lost_VBN in_IN the_DT shadow_NN of_IN psychiatric_JJ illnesses_NNS ._.
353162_CD is_VBZ our_PRP$ next_JJ 406381_CD targets_NNS inflammatory_JJ and_CC neuropathic_JJ pain_NN and_CC is_VBZ expected_VBN generation_NN noradrenaline_NN dopamine_JJ re-uptake_NN inhibitor_NN NDRI_NNP ,_, a_DT new_JJ to_TO lead_VB to_TO greater_JJR effectiveness_NN across_IN a_DT range_NN of_IN pain_NN types_NNS ._.
anti-depressant_JJ with_IN the_DT potential_NN for_IN greater_JJR control_NN of_IN symptoms_NNS ._.
The_DT Research_NNP &_CC Development_NNP meetings_NNS The_DT path_NN to_TO products_NNS GSKs_NNS R&D_NNP is_VBZ structured_VBN to_TO take_VB CEDDs_NNS that_WDT emphasise_VBP flexibility_NN and_CC unveiled_VBD to_TO analysts_NNS ._.
Thirty_CD five_CD GSKs_NNS goal_NN is_VBZ to_TO bring_VB more_JJR than_IN advantage_NN of_IN size_NN at_IN the_DT beginning_NN therapeutic_JJ focus_NN ._.
promising_JJ compounds_NNS ,_, selected_VBN 20_CD NCEs_NNS to_TO phase_VB III_NNP development_NN and_CC end_NN of_IN the_DT R&D_NNP process_NN where_WRB for_IN novelty_NN ,_, impact_NN on_IN disease_NN and_CC over_IN the_DT next_JJ three_CD years_NNS ,_, leading_VBG large-scale_JJ research_NN is_VBZ needed_VBN The_DT CEDD_NNP structure_NN aims_VBZ to_TO make_VB commercial_JJ potential_NN ,_, were_VBD outlined_VBN ._.
to_TO an_DT anticipated_JJ record_NN number_NN such_JJ as_IN screening_VBG targets_NNS against_IN the_DT R&D_NNP process_NN more_RBR effective_JJ and_CC Some_DT of_IN these_DT compounds_NNS are_VBP of_IN filings_NNS in_IN the_DT next_JJ five_CD years_NNS ._.
It_PRP is_VBZ compounds_NNS and_CC conducting_VBG largeefficient_JJ ,_, and_CC our_PRP$ broad_JJ and_CC deep_JJ featured_VBN on_IN this_DT page_NN along_IN with_IN expected_VBN that_IN over_IN 20_CD of_IN these_DT have_VBP scale_NN clinical_JJ trials_NNS ._.
However_RB ,_, to_TO bridge_VB pipeline_NN is_VBZ an_DT early_JJ sign_NN of_IN the_DT images_NNS from_IN our_PRP$ R&D_NNP organization_NN ._.
the_DT potential_JJ to_TO reach_VB blockbuster_NN the_DT interface_NN between_IN discovery_NN and_CC evolution_NN in_IN this_DT approach_NN ._.
status_NN of_IN annual_JJ sales_NNS of_IN $_$ 1_CD billion_CD development_NN ,_, the_DT organization_NN is_VBZ GSK_NNP currently_RB has_VBZ 148_CD projects_NNS in_IN 600_CD million_CD ._.
divided_VBN into_IN small_JJ biotech-like_JJ In_IN December_NNP ,_, R&D_NNP presentations_NNS were_VBD clinical_JJ development_NN ,_, comprising_VBG 83_CD business_NN units_NNS called_VBN Centres_NNP of_IN made_VBN in_IN the_DT UK_NNP and_CC USA_NNP ,_, where_WRB new_JJ chemical_NN entities_NNS ,_, 45_CD product_NN line_NN Excellence_NN for_IN Drug_NN Discovery_NNP GSK_NNP 's_POS pipeline_NN of_IN future_JJ products_NNS was_VBD extensions_NNS and_CC 20_CD vaccines_NNS ._.
